Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Martek, Numico deal

This article was originally published in The Tan Sheet

Executive Summary

Nutritional oil manufacturer Martek Biosciences will exclusively supply infant formula producer Numico with ARA and microbially-derived DHA for its infant formula products under a 15-year deal between the firms, Martek announces Feb. 19. The agreement extends an existing license agreement that has been in place since 1994, but allows Numico to terminate the arrangement as early as January 2012, Martek states. "With this new agreement, more than 70 percent of Martek's business in the infant formula market is subject to multi-year sole source agreements," firm notes...

You may also be interested in...



Martek Revenues Grow On International Demand For life’sDHA

Sales of life'sDHA to international infant formula manufacturers helped drive nutritional oil developer Martek Biosciences' revenue up 18 percent to a record $82.9 million during its fiscal 2008 first quarter, the firm says

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS101397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel